Table 1.
Demographics, clinical information, and scale responses
| Mean | sd | |
|
| ||
| Age at survey | 63.0 | 12.54 |
| Age at diagnosis | 59.1 | 12.36 |
|
| ||
| % | ||
|
| ||
| Gender | ||
| Male | 57 | |
| Female | 43 | |
| Race | ||
| White | 94 | |
| Asian | 1 | |
| Unknown | 5 | |
| Primary language | ||
| English | 99 | |
| Other | 1 | |
| Stage at diagnosis | ||
| I | 11 | |
| II | 21 | |
| III | 16 | |
| IV | 52 | |
| Initial immunotherapy regimen | ||
| Ipilimumab+nivolumab | 57 | |
| Ipilimumab | 28 | |
| Pembrolizumab | 12 | |
| Nivolumab | 3 | |
| Durvalumab | 2 | |
| Prior Treatment | ||
| Chemotherapy | 22 | |
| Radiation | 16 | |
| 2nd immunotherapy regimen | 38 | |
| 3rd immunotherapy regimen | 5 | |
|
| ||
| Mean | sd | |
|
| ||
| EORTC-QLQ30 Subscales | ||
| Global QOL | 84.0 | 19.51 |
| Social | 89.2 | 19.80 |
| Emotional | 84.6 | 16.74 |
| Physical | 90.7 | 16.45 |
| Role | 89.3 | 20.98 |
| Cognitive | 87.1 | 16.47 |
| Financial difficulties | 88.4 | 23.92 |
| COST | 30.0 | 9.46 |